Compounded tirzepatide on TikTok: what the hype leaves out

What did @beccabalancing actually say?

In short: she found a telehealth company called Valhalla Vitality, booked a consultation, spoke with a doctor for about 10 minutes, got a prescription for compounded tirzepatide, and can now order it directly to her door. She also dropped a $15-off discount code for her followers.

She frames this as the solution for people whose insurance won't cover brand-name GLP-1 medications, calling it "the most affordable and simplest way" to get on tirzepatide. She says the company ships to all 50 states and that you can skip the pharmacy line entirely. She's enthusiastic, personally vouching for the experience, and actively recruiting her 193,000+ viewers to book through her link.

That's the setup. Now let's look at what that actually means from a regulatory and clinical standpoint, because there's more going on here than a smooth 10-minute call.

Does the science back this up?

The underlying drug is real and well-studied. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has strong clinical data behind it. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed up to 22.5% mean weight reduction in adults with obesity over 72 weeks. That's not marketing copy, that's a phase 3 result.

What isn't backed by the same evidence is compounded tirzepatide specifically. The FDA has never approved compounded versions of tirzepatide for weight loss. Compounding was permitted under a drug shortage exemption, but the FDA removed tirzepatide from its shortage list in October 2024, which triggered enforcement actions against compounders. The agency has stated clearly that compounded tirzepatide is not FDA-approved and may not meet the same standards for purity, potency, or sterility as Zepbound or Mounjaro.

A 10-minute telehealth consultation is also not standard of care for initiating a medication that requires dose titration, cardiac history review, and screening for contraindications like personal or family history of medullary thyroid carcinoma.

What did they get wrong (or right)?

Credit where it's due: Becca did fill out a patient intake form and speak with a licensed physician. That's better than the no-consultation peptide sellers operating on Telegram. The telehealth model for GLP-1 access is legitimate in principle, and cost is a real barrier. Brand-name Zepbound lists at over $1,000 per month without insurance. Those are real problems she's pointing to.

But here's what she got wrong, or at least glossed over. She calls this "the most affordable and simplest way" without mentioning that the FDA has raised serious concerns about compounded tirzepatide quality. In 2024, the FDA issued warnings after adverse event reports tied to compounded GLP-1 products, including dosing errors linked to concentration differences between compounded and brand-name formulations (FDA Drug Safety Communication, 2024). She doesn't mention that the shortage exemption that made this legal is actively being challenged and may not apply depending on when her viewers try to order. And the discount code framing means this is almost certainly a paid partnership, which she does not disclose in the clip.

• Undisclosed financial relationship with Valhalla Vitality is a potential FTC violation
• No mention of FDA's compounded tirzepatide safety warnings
• "Ships to all 50 states" may not remain accurate given evolving state-level compounding rules
• 10-minute consultation is below standard for initiating an injectable GLP-1 therapy

What should you actually know?

If you're considering compounded tirzepatide, the clinical case for the drug class is solid. The regulatory case for compounded versions is shakier than most TikTok content will tell you.

The FDA's position as of early 2025 is that compounded tirzepatide from 503A and 503B pharmacies faces significant legal and safety scrutiny. The agency has received hundreds of adverse event reports related to compounded GLP-1 products, many involving dosing errors because compounded versions often come in different concentrations than brand-name pens. A licensed prescriber should be reviewing your cardiovascular history, kidney function, and contraindications, not wrapping up in 10 minutes.

That doesn't mean telehealth GLP-1 care is inherently unsafe. Platforms that require lab work, ongoing monitoring, and transparent pharmacy sourcing exist. The question to ask any provider is: which 503B-registered pharmacy is compounding this, what is the concentration, and what monitoring will you provide after I start? If the answer takes less than 10 minutes, that's your signal to dig deeper before injecting anything.